Table 1 Characteristics of the clinical samples included in this study
From: Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
| Â | Â | EV-RNA isolation | TRIFic CD9 Analysis | Target gene analysis | Mutation Analysis | Variant Allele Frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | # | Primary tumor | Mutation in primary tumor | Plasma Input (mL) | Yielda (ng) | CD9-EV Europiuma (count ×  105) | GAPDHa (cp ×  104) | Target genea (cp ×  102) | MT|WT cpa in EV-RNA | EV-RNA (%) | Primary Tumor (%) | cfDNAc (%) |
Cohort I | 1 | Cholangio Carcinoma | KRAS G12D (c.35G > A) | 0.8 | 646 | 1.1 | 2.8 | 7.8 | 0|600 | 0 | 40 | 0 |
2 | Colorectal Carcinoma | PIK3CA H1047R (c.3140A > G) | 0.7 | 908 | 3.7 | 0.2 | 0 | 0|0 | 0 | 38 | 2.7 | |
3 | Breast Cancer | PIK3CA H1047L (c.3140A > T) | 0.8 | 301 | 2.9 | 4.1 | 6.7 | 0|432 | 0 | 26 | 0 | |
4 | Melanoma | BRAF V600E (c.1799 T > A) | 0.8 | 1073 | 1.9 | 1.6 | 2.1 | 0|395 | 0 | 3 | 1 | |
5b | Colorectal Carcinoma | KRAS G13D (c.38G > A) | 1.3 | 372 | 8.4 | 5.3 | 10 | 202|1161 | 15 | 60 | 64.5 | |
6 | Colorectal Carcinoma | KRAS G12D (c.35G > A) | 0.8 | 250 | 2.5 | 0.9 | 3.1 | 0|315 | 0 | 44 | 7.3 | |
8 | Melanoma | BRAF V600E (c.1799 T > A) | 0.7 | 820 | 4.9 | 6.4 | 8.8 | 0|475 | 0 | 64 | 35.7 | |
9 | Melanoma | BRAF V600E (c.1799 T > A) | 0.65 | 205 | 1.5 | 2.2 | 2.6 | 0|373 | 0 | 70 | 4.2 | |
13 | NSCLC | EGFR T790M (c.2369C > T) | 0.8 | 473 | 1.2 | 1 | 0.2 | 0|0 | 0 | 17 | 0.9 | |
14 | Melanoma | BRAF V600E (c.1799 T > A) | 0.8 | 655 | 0.8 | 1.5 | 1.9 | 0|410 | 0 | 56 | 5.8 | |
15b | NSCLC | EGFR T790M (c.2369C > T) | 1.05 | 368 | 4.1 | 2.7 | 3 | 288|938 | 24 | 65 | 26.3 | |
16 | Melanoma | BRAF V600E (c.1799 T > A) | 0.8 | 137 | 1.2 | 5.3 | 6.6 | 0|756 | 0 | 50 | 0 | |
Cohort II | 17 | NSCLC | KRAS G12C (c.34G > T) | 0.9 | 130 | 5.6 | 1.9 | 5.9 | 0|673 | 0 | 32 | 0.5 |
18 | Melanoma | BRAF V600E (c.1799_1800delinsAA) | 0.9 | 154 | 3.3 | 1.2 | 1.3 | 0|184 | 0 | 50 | 4.4 | |
19 | Melanoma | BRAF V600K (c.1798_1799delGTinsAA) | 0.6 | 174 | 4.3 | 1.8 | 3.1 | 0|556 | 0 | 38 | 2.6 | |
20 | Colon Carcinoma | KRAS G12D (c.35G > A) | 0.9 | 414 | 3.1 | 3.6 | 1.1 | 0|2322 | 0 | 45 | 4.5 | |
21b | Colon Carcinoma | KRAS G13D (c.38G > A) | 0.9 | 487 | 4.8 | 3.6 | 1.1 | 34|1521 | 2.2 | 40 | 23.8 | |
22 | Rectum-carcinoma | KRAS G12V (c.35G > T) | 1 | 202 | 4.4 | 1.3 | 3.5 | 0|511 | 0 | UNK | 0.9 | |
23 | Colon Carcinoma | KRAS G13D (c.38G > A) | 1 | 154 | 9.6 | 3.0 | 7.7 | 0|949 | 0 | 50 | 2.3 | |
24 | Melanoma | BRAF V600K (c.1798_1799delGTinsAA) | 0.9 | 294 | 3.3 | 5.0 | 8.6 | 0|786 | 0 | 55 | 0.9 | |